Background: Haratala is described as the Dhatu visha and it contains arsenic and sulfur. Arsenic is a heavy metal that may lead to acute or chronic heavy metal toxicity. Although Haratala is effective and popular as Rasamanikya, it is not used as Rasayana or therapeutic drug in routine practice either in pure or in Bhasma form. It is used as a main drug or an auxiliary drug to prepare formulation. Aim: To focus on the various utilities of Haratala, so that it can be safely used in the clinical practice in a wide range of indications. Review results: In the literature available, it is observed that along with therapeutic utility of Haratala, Haratala Bhasma is used as Rasayana. But arsenic present in Haratala may cause toxicity if shodhana and marana of Haratala are not conducted properly. It is observed from the previous research that shodhana may enhance the synergistic effect of Haratala in cellular apoptosis for the treatment of leukemia. Marana may provide safer bioassimilability before their use in most of the formulations in which it may act as an antagonist and subside the toxicity of the formulations. Conclusion: Haratala Bhasma is indicated in various disease conditions. Hence, it can be used as Avasthika Rasayana. But during its use, safety of the drug should be ensured by following proper shodhana and marana procedures. Clinical significance: Studies should be conducted to observe its efficacy in healthy individuals as Rasayana and in patients of acute promyelocytic leukemia (APL) as an adjuvant drug.